NEW ORLEANS, Jan. 26, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 5, 2018 to file lead plaintiff applications in a securities class action lawsuit against OSI Systems Inc. (Nasdaq:OSIS), if they purchased the Company’s securities between August 16, 2013 and December 6, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
Get Help
OSI Systems investors should visit us at https://www.claimsfiler.com/cases/view-osi-systems-inc-securities-litigation-1 or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
OSI Systems and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 6, 2017, Muddy Waters Research reported several allegations of corrupt business practices by the Company. Specifically, that an Albania concession was acquired through bribery or other improper measures; an unannounced transfer of 49% of its project company, S2 Albania SHPK, to an Albanian holding company for consideration of less than $5.00; and, based on information from former employees, other unlawful acts including improper sales, bribery and fraud.
On this news, the price of OSI Systems’ shares plummeted $24.55 per share, or 29.2%.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


Anta Sports Expands Global Footprint With Strategic Puma Stake
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



